SH2 PROFILING

SH2 分析

• 批准号: 7607598
• 负责人: BRUCE J. MAYER
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607598
• 关键词: Binding; Classification; Computer Retrieval of Information on Scientific Projects Database; DNA; Data; Defect; Diagnostic; Funding; Grant; Health; Hematopoietic Neoplasms; Institution; Molecular; Molecular Diagnostic Techniques; Molecular Profiling; Patients; Play; Proteins; Purpose; Research; Research Personnel; Resources; Role; Sampling; Signal Transduction; Source; Standards of Weights and Measures; Techniques; Tertiary Protein Structure; Testing; United States National Institutes of Health; base; neoplastic cell; novel; prognostic; research study; response; tool; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is a need for molecular diagnostic tools that will allow the classification of tumors beyond what is currently possible using standard techniques. Ideally, markers will be identified that will have prognostic value (correlate with response to particular treatments, for example). Expression profiling using Complementary Deoxyribonucleic acid (cDNA) microarrays is now being tested for this purpose, but is at present cumbersome, costly, and is unlikely to give any information about the molecular defects in the tumor cell. We are developing a novel molecular diagnostic technique based on the profile of proteins in a tumor sample that bind to certain protein domains known to play an important role in signal transduction. In preliminary experiments this technique can identify different binding profiles in similar tumor types, suggesting it may be a valuable molecular diagnostic tool. The resulting profiles may also be informative about the molecular defects in a particular tumor. We propose to test this technique on samples from hematopoietic malignancies available at the UConn Health Center to establish the feasibility of implementation on a larger scale. Ultimately, if the technique is sufficiently robust and reproducible, we will correlate profiling data with patient information to determine whether the interaction profiling provides information with prognostic value.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 需要分子诊断工具，这种工具将允许对肿瘤进行分类，而不是目前使用标准技术所能做到的。理想情况下，将确定具有预后价值的标记物(例如，与对特定治疗的反应相关)。使用互补脱氧核糖核酸(CDNA)微阵列的表达谱分析现在正在进行这一目的的测试，但目前繁琐、昂贵，而且不太可能提供任何关于肿瘤细胞中分子缺陷的信息。我们正在开发一种新的分子诊断技术，该技术基于肿瘤样本中结合到某些已知在信号转导中起重要作用的蛋白质结构域的蛋白质图谱。在初步实验中，这项技术可以在类似的肿瘤类型中识别不同的结合谱，这表明它可能是一种有价值的分子诊断工具。由此得到的轮廓也可能是关于特定肿瘤中的分子缺陷的信息。我们建议在康涅狄格州大学健康中心提供的血液系统恶性肿瘤样本上测试这项技术，以确定在更大范围内实施的可行性。最终，如果该技术足够健壮和可重复性，我们将把侧写数据与患者信息关联起来，以确定交互侧写是否提供了具有预后价值的信息。